FOR US HEALTHCARE PROFESSIONALS ONLY

INVEGA SUSTENNA^® is the only long-acting injectable proven to reduce the risk of both all-cause and psychiatric, 30-day hospital readmissions vs oral atypical antipsychotics¹*^†‡

In a retrospective claims analysis of patients receiving INVEGA SUSTENNA^®:

Adults 18-35 years had a
27% lower risk of being rehospitalized within 30 days
vs patients on oral atypical antipsychotics (OAA)¹*

Adults in the overall population had a
21% lower risk of being rehospitalized within 30 days
vs patients on OAA¹*

OAA MEDICATION INCLUDED:

aripiprazole, asenapine maleate, brexpiprazole, cariprazine, iloperidone, lurasidone, olanzapine, paliperidone, quetiapine, quetiapine fumarate, risperidone, ziprasidone¹

ICD-9=International Classification of Diseases, Ninth Revision. ICD-10=International Classification of Diseases, Tenth Revision.

*P<0.001.

^†Patients were required to have at least 1 schizophrenia-related index hospitalization during the study period defined using ICD-9 code 295.xx or ICD-10 codes F20.xx, F21.xx, or F25.xx. Coding selection included populations outside of the 2 approved indications of INVEGA SUSTENNA^®. About 40% of the overall population had schizoaffective disorder, 33% had schizophrenia, and 3% had other diagnoses; however, more than 1 type per patient was possible. About 40% of the young adult population had schizoaffective disorder, 36% had schizophrenia, and 4% had other diagnoses; however, more than 1 type per patient was possible.¹

^‡As of January 2025.

Hospital readmission analysis study design¹

During the study period, “schizophrenia-related index hospitalizations” were defined as hospitalization with:

1A primary or admission diagnosis of schizophrenia

2A primary or admission diagnosis of mental disorder and a secondary diagnosis of schizophrenia

3A primary or admission diagnosis of injury or poisoning and a secondary diagnosis of schizophrenia

The Premier Perspective Comparative Hospital database, which encompasses inpatient services from over 700 hospitals in the US, was used to retrospectively compare rehospitalizations of adults with schizophrenia treated with paliperidone palmitate (n=8,578) or oral atypical antipsychotics (n=306,252) from January 2009 to December 2016.

Odds ratios were presented as a measure of effect, along with 95% confidence intervals and P values. A multivariate generalized estimating equation model, adjusted for a variety of demographic and clinical factors, was used to estimate the odds of rehospitalization for patients on paliperidone palmitate and oral atypical antipsychotics.

This study was not designed to measure the efficacy of INVEGA SUSTENNA^®.

Limitations

Results of retrospective studies can be affected by coding-entry errors, missing data, and residual confounding. The DSM-5^® criteria used in the clinical setting to diagnose patients with schizophrenia and schizoaffective disorders are not identical to the ICD-9 and ICD-10 codes used in this study to identify patients with schizophrenia and schizoaffective disorders. Since the date of the first schizophrenia diagnoses was not available, age was used as a surrogate for time from diagnosis. Patients could only be traced for hospitalizations occurring at the same facility, which could lead to underestimation of rehospitalization rates.

DSM-5=Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; ICD-9=International Statistical Classification of Diseases, Ninth Revision; ICD-10=International Statistical Classification of Diseases, Tenth Revision.

How can you help your patients stay on treatment during their transition from the inpatient to outpatient setting?

According to the American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia²:

“A long-acting injectable formulation of an antipsychotic may be considered when patients are transitioning between settings (eg, at inpatient discharge, on release from a correctional facility) when future adherence is uncertain, and the risk of reduced adherence may be increased.”²

A few simple adjustments in communication and integration between treatment teams may also help your patients make a successful transition to the outpatient setting.

Best Practices to Improve Care Transitions

Explore actionable best practices to address 7 common challenges associated with the continuity of care.

Download Best Practices to Improve Care Transitions

Explore actionable best practices to address 7 common challenges associated with the continuity of care.

Download Best Practices to Improve Care Transitions

IN A SURVEY OF ADULT PATIENTS WITH SCHIZOPHRENIA:

84%—after having mental health emergencies—
said they regret not trying a long-acting option earlier.³*

*Based on results from a survey of randomly selected adult patients with schizophrenia (N=200). A subgroup of patients were adults who have previously tried or are currently taking LAIs (n=106), and among those users, 84% (n=89/106) agreed strongly, mostly, or somewhat (on a 7-point scale) indicated they regret not trying a long-acting option earlier.³

LAI=long-acting injectable.

References: 1. Pilon D, Amos TB, Kamstra R, et al. Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis. Curr Med Res Opin. 2019;35(1):41-49. 2. The American Psychiatric Association. Practice Guideline for the Treatment of Patients With Schizophrenia. 3rd ed. Accessed March 18, 2025. https://psychiatryonline.org/doi/pdf/10.1176/appi.books.9780890424841 3. Data on file. Janssen Pharmaceuticals, Inc.

INVEGA SUSTENNA® is the only long-acting injectable proven to reduce the risk of both all-cause and psychiatric, 30-day hospital readmissions vs oral atypical antipsychotics1*†‡

INVEGA SUSTENNA^® is the only long-acting injectable proven to reduce the risk of both all-cause and psychiatric, 30-day hospital readmissions vs oral atypical antipsychotics¹*^†‡